Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
IGM Biosciences, Inc. (IGMS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces Second Quarter 2023 Financial Results – Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., August 3, 2023"
05/12/2023 8-K Quarterly results
Docs: "IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update – Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway – – Plans to present additional non-randomized clinical data for 3 mg/kg of IGM-8444 plus FOLFIRI, with and without bevacizumab, in the middle of 2023 – – Plans to begin clinical testing of imvotamab in severe systemic lupus erythematosus and severe rheumatoid arthritis – MOUNTAIN VIEW, Calif., May 12, 2023"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"IGM Biosciences Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update"
11/04/2021 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update"
08/09/2021 8-K Quarterly results
Docs: "IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update"
05/06/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of The Securities Exchange Act of 1934 Date of Report November 5, 2020 IGM Biosciences, Inc. Delaware 001-39045 77-0349194 325 E. Middlefield Road Mountain View, CA 94043 965-7873 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 un...",
"IGM Biosciences Announces Third Quarter 2020 Financial Results and Provides Corporate Update"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
Docs: "FORM 8-K",
"IGM Biosciences Announces First Quarter 2020 Financial Results and Provides Corporate Update"
03/26/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy